Optimum treatment of severe sepsis and septic shock: Evidence in support of the recommendations

Disease-a-Month

Volumn 50, Issue 4, 2004, Pages 168-213

  Balk, Robert A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ADRENALIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTITHROMBIN; CEFIPIME; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CORTICOSTEROID; DOBUTAMINE; DOPAMINE; LEVOFLOXACIN; MACROLIDE; METHYLPREDNISOLONE SODIUM SUCCINATE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; PHENYLEPHRINE; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; VANCOMYCIN; VASOPRESSIN;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CONSERVATIVE TREATMENT; DISEASE CLASSIFICATION; DISEASE SEVERITY; EARLY DIAGNOSIS; HEMODYNAMIC MONITORING; HEMODYNAMICS; HEMOFILTRATION; HOST RESISTANCE; HUMAN; LUNG VENTILATION; METABOLISM; MORBIDITY; OXYGENATION; PATHOPHYSIOLOGY; PLASMAPHERESIS; PREDICTION; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIAE;

EID: 2342530850     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2003.12.003     Document Type: Article

References (177)

1. Balk R.A. Severe sepsis and septic shock definitions, epidemiology, and clinical manifestations. Crit Care Clin. 16:2000;179-192
2. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States analysis of incidence, outcome, and associated costs of care. Crit Care Med. 29:2001;1303-1310
3. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 348:2003;1546-1554
4. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 101:1992;1644-1655
5. Bone R.C., Grodzin C.J., Balk R.A. Sepsis a new hypothesis for pathogenesis of the disease process. Chest. 112:1997;235-243
6. International Sepsis Definitions Conference, Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. 2001 SCCM/ESICM/ACCP/ATS/ SIS International Sepsis Definitions Conference. Crit Care Med. 31:2003;1250-1256
7. Rangel-Frausto M.S., Pittet D., Costigan M., Hwang T., Davis C.S., Wenzel R.P. The natural history of the systemic inflammatory response syndrome (SIRS). JAMA. 273:1995;117-123
8. Division of Vital Statistics, Minino A.M., Smith B.L. Deaths preliminary data for 2000. Natl Vital Stat Rept. 49:2001;1-40
9. Sands K.E., Bates D.W., Lanken P.N., Graman P.S., Hibberd P.L., Kahn K.L., et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 278:1997;234-240
10. Wheeler A.P., Bernard G.R. Treating patients with severe sepsis. N Engl J Med. 340:1999;207-214
11. Friedman G., Silva E.S., Vincent J.L. Has the mortality of septic shock changed with time? Crit Care Med. 26:1998;2078-2086
12. Bone R.C., Fisher C.J. Jr, Clemmer T.P., Slotman G.J., Metz C.A., Balk R.A. Sepsis syndrome a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med. 17:1989;389-393
13. Foreman M.G., Mannino D.M., Moss M. Cirrhosis as a risk factor for sepsis and death. Chest. 124:2003;1016-1020
14. Holmes C.L., Russell J.A., Walley K.R. Genetic polymorphisms in sepsis and septic shock. Chest. 124:2003;1103-1115
15. Lorenz E., Mira J.P., Frees K.L., Schwartz D.A. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med. 162:2002;1028-1032
16. Angele M.K., Schwacha M.G., Ayala A., Chaudry I.H. Effect of gender and sex hormones on immune response following shock. Shock. 14:2000;81-90
17. Strauss R., Wehler M., Mehler K., Kreutzer D., Koebnick C., Hahn E.G. Thrombocytopenia in patients in the medical intensive care unit bleeding prevalence, transfusion requirements, and outcome. Crit Care Med. 30:2002;1765-1771
18. Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. Crit Care Med. 27:1999;887-892
19. Casey L.C., Balk R.A., Bone R.C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 119:1993;771-778
20. Lobo S.M.A., Lobo F.R.M., Bota D.P., Lopes-Ferreira F., Soliman H.M., Melot C., et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest. 123:2003;2043-2049
21. Claeys R., Vinken S., Spapen H., ver Elst K., Decochez K., Huyghens L., et al. Plasma procalcitonin and C-reactive protein in acute septic shock clinical and biological correlates. Crit Care Med. 30:2002;757-762
22. Luzzani A., Polati E., Dorizzi R., Rungatscher A., Pavan R., Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 31:2003;1737-1741
23. Levels J.H.M., Lemaire L.C.J.M., van den Ende A.E., van Deventer S.J.H., van Lanschot J.J.B. Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure. Crit Care Med. 31:2003;1647-1653
24. Toh C.H., Ticknor L.O., Downey C., Giles A.R., Paton R.C., Wenstone R. Early identification of sepsis and mortality risks through simple, rapid, clot-waveform analysis implications of lipoprotein-complexed C reactive protein formation. Intensive Care Med. 29:2003;55-61
25. Marshall J.C., Walker P.M., Foster D.M., Harris D., Ribero M., Paice J., et al. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit Care. 6:2002;342-348
26. Balk R.A. Endotoxin in critically ill patients why a reliable test could be beneficial. Crit Care. 6:2002;289-290
27. Balk R.A. Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. Crit Care Clin. 16:2000;337-352
28. Bone R.C. The pathogenesis of sepsis. Ann Intern Med. 115:1991;457-469
29. Bone R.C. Gram-negative sepsis background, clinical features, and intervention. Chest. 100:1991;802-808
30. Bone R.C. Modulators of coagulation a critical appraisal of their role in sepsis. Arch Intern Med. 152:1992;1381-1389
31. Natanson C., Hoffman W.D., Suffredini A.F., Eichacker P.Q., Danner R.L. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med. 120:1994;771-783
32. Dinarello C.A. Proinflammatory and antiinflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 112:(suppl):1997;S321-329
33. Galley H.F., Webster N.R. The immuno-inflammatory cascade. Br J Anaesth. 77:1996;11-16
34. Gando S., Nanzaki S., Sasaki S., Aoi K., Kemmotsu O. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med. 26:1998;2005-2009
35. Balk R.A., Goyette R.E. Multiple organ dysfunction syndrome in patients with severe sepsis: more than just inflammation. International Congress and Symposium Series No. 249. 2002;Royal Society of Medicine Press Ltd, London, England.. p 39-60
36. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med. 348:2003;138-150
37. Fourrier F., Chopin C., Goudemand J., Hendrycx S., Caron C., Rime A., et al. Septic shock, multiple organ failure and disseminated intravascular coagulation compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 101:1992;816-823
38. Bone R.C. Why sepsis trials fail. JAMA. 276:1996;565-566
39. Cronin L., Cook D.J., Carlet J., Heyland D.K., King D., Lansang M.A., et al. Corticosteroid treatment for sepsis a critical appraisal and meta-analysis of the literature. Crit Care Med. 23:1995;1430-1439
40. Zeni F., Freeman B., Natanson C. Antiinflammatory therapies to treat sepsis and septic shock a reassessment. Crit Care Med. 25:1997;1095-1100
41. Faust S.N., Levin M., Harrison O.B., Goldin R.D., Lockhart M.S., Kondaveeti S., et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 345:2001;408-416
42. Yan S.B., Helterbrand J.D., Hartman D.L., Wright T.J., Bernard G.R. Low levels of protein C are associated with poor outcome in severe sepsis. Chest. 120:2001;915-922
43. Lorente J.A., Garcia-Frade L.J., Landin L., de Pablo R., Torrado C., Renes E., et al. A Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest. 103:1993;1536-1542
44. Powars D., Larsen R., Johnson J., Hulbert T., Sun T., Patch M.J., et al. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis. 17:1993;254-261
45. Boldt J., Papsdorf M., Rothe A., Kumle B., Piper S. Changes of the hemostatic network in critically ill patients is there a difference between sepsis, trauma, and neurosurgery patients? Crit Care Med. 28:2000;445-450
46. Fisher C.J., Yan S.B. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med. 28:(suppl):2000;S49-56
47. Esmon C.T. Introduction are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood. 95:2000;1113-1116
48. Mammen E.F. Antithrombin III and sepsis. Intensive Care Med. 24:1998;649-650
49. Corrigan J.J. Jr, Ray W.L., May N. Changes in the blood coagulation system associated with septicemia. N Engl J Med. 279:1968;851-856
50. Dellinger R.P. Current therapy for sepsis. Infect Dis Clin North Am. 13:1999;495-509
51. Parrillo J.E., Parker M.M., Natanson C., Suffredini A.F., Danner R.L., Cunnion R.E., et al. Septic shock in humans advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med. 113:1990;227-242
52. Kreger BE, Craven DE, Carling PC, McCabe WR. Gram-negative bacteremia. III: Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 1980;68:332-43
53. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV: Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980;68:344-55
54. Kollef M.H., Sherman G., Ward S., Fraser V.J. Inadequate antimicrobial treatment of infections a risk factor for hospital mortality among critically ill patients. Chest. 115:1999;462-474
55. Bochud P.Y., Glauser M.P., Calandra T. Antibiotics in sepsis. Intensive Care Med. 27:(suppl):2001;S33-48
56. Simon D., Trenholme G. Antibiotic selection for patients with septic shock. Crit Care Clin. 16:2000;215-231
57. Jimenez M.F., Marshall J.C. Source control in the management of sepsis. Intensive Care Med. 27:(suppl):2001;S49-62
58. Meehan T.P., Fine M.J., Krumholz H.M., Scinto J.D., Galusha D.H., Mockalis J.T., et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 278:1997;2080-2084
59. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 118:2000;146-155
60. Luna C.M., Vujacich P., Niederman M.S., Vay C., Gherardi C., Matera J., et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 111:1997;676-685
61. Dellinger R.P. Cardiovascular management of septic shock. Crit Care Med. 31:2003;946-955
62. Vincent J.L. Hemodynamic support in septic shock. Intensive Care Med. 27:(suppl):2001;S80-92
63. Connors A.F. Jr, Speroff T., Dawson N.V., Thomas C., Harrell F.E. Jr, Wagner D., et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA. 276:1996;889-897
64. Canadian Critical Care Clinical Trials Group, Sandham J.D., Hull R.D., Brant R.F., Knox L., Pineo G.F., Doig C.J., et al. A randomized controlled trial of the use of pulmonary artery catheters in high risk surgical patients. N Engl J Med. 348:2003;5-14
65. French Pulmonary Artery Catheter Study Group, Richard C., Warszawski J., Anguel N., Deye N., Combes A., Barnoud D., et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome. JAMA. 290:2003;2713-2720
66. Landry D.W., Oliver J.A. The pathogenesis of vasodilatory shock. N Engl J Med. 345:2001;588-595
67. Schierhout G., Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients a systematic review of randomized trials. BMJ. 316:1998;961-964
68. Monteiro Pacheco A. Jr, Martins Coimbra R.S., Kreimeier U., Frey L., Messmer K. Hypertonic volume therapy feasibility in the prevention and treatment of multiple organ failure and sepsis. Rev Paul Med. 113:1995;1053-1060
69. Loomis W.H., Namiki S., Hoyt D.B., Junger W.G. Hypertonicity rescues T cells from suppression by trauma-induced antiinflammatory mediators. Am J Physiol Cell Physiol. 281:2001;C840-848
70. de Carvalho H., Matos J.A., Bouskela E., Svensjo E. Vascular permeability increase and plasma volume loss induced by endotoxin was attenuated by hypertonic saline with or without dextran. Shock. 12:1999;75-80
71. Corwin H.C., Gettinger A., Pearl R.G., Fink M.P., Levy M.M., Shapiro, et al. Efficacy of recombinant human erythropoietin in critically ill patients. JAMA. 288:2002;2827-2835
72. Hebert P.C., Wells G., Blajchman M.A., Marshall J., Martin C., Pagliarello G., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 340:1999;409-417
73. Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 345:2001;1368-1377
74. Steel A., Bihari D. Choice of catecholamine does it matter? Curr Opin Crit Care. 6:2000;347-353
75. Bellomo R., Chapman M., Finfer S., Hickling K., Myburgh J. Low-dose dopamine in patients with early renal dysfunction a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 356:2000;2139-2143
76. Kellum J.A., Decker J.M. Use of dopamine in acute renal failure a meta-analysis. Crit Care Med. 29:2001;1526-1531
77. Marik P.E., Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA. 272:1994;1354-1357
78. Martin C., Viviand X., Leone M., Thirion X. Effect of norepinephrine on the outcome of septic shock. Crit Care Med. 28:2000;2758-2765
79. Grover R., Zaccardelli D., Colice G., Guntupalli K., Watson D., Vincent J.L. An open-label dose escalation study of the nitric oxide synthase inhibitor N(G)-methyl-L-arginine hydrochloride (546C88) in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med. 27:1999;913-922
80. Grover R., Lopez A., Lorente J., et al. Multicenter, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88 effect on survival in patients with septic shock. [abstract] Crit Care Med. 27:1999;A33
81. Rivers E.P., Gaspari M., Saad G.A., Mlynarek M., Fath J., Horst H.M., et al. Adrenal insufficiency in high-risk surgical ICU patients. Chest. 119:2001;889-896
82. Bollaert P.E., Charpentier C., Levy B., Debouverie M., Audibert G., Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 26:1998;645-650
83. Briegel J., Forst H., Haller M., Schelling G., Kilger E., Kuprat G., et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock a prospective, randomized, double-blind, single-center study. Crit Care Med. 27:1999;723-732
84. Annane D., Sebille V., Charpentier C., Bollaert P.E., Francois B., Korach J.M., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 288:2002;862-871
85. Cooper M.S., Stewart P.M. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 348:2003;727-734
86. Dorin R.I., Qualls C.R., Crapo L.M. Diagnosis of adrenal insufficiency. Ann Intern Med. 139:2003;194-204
87. Manglik S., Flores E., Lubarsky L., Fernandez F., Chhibber V., Tayek J.A. Glucocorticoid insufficiency in patients who present to the hospital with severe sepsis a prospective clinical trial. Crit Care Med. 31:2003;1668-1675
88. Marik P.E., Zaloga G.P. Adrenal insufficiency in the critically ill a new look at an old problem. Chest. 122:2002;1784-1796
89. Rello J., Diaz E. Pneumonia in the intensive care unit. Crit Care Med. 31:2003;2544-2551
90. Ware L.B., Matthay M.A. The acute respiratory distress syndrome. N Engl J Med. 342:2000;1334-1348
91. Gattinoni L., Brazzi L., Pelosi P., Latini R., Togoni G., Pesenti, Fumugalli. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med. 333:1995;1025-1032
92. Russell J.A., Phang P.T. The oxygen delivery/consumption controversy. Am J Respir Crit Care Med. 149:1994;533-537
93. Hayes M.A., Timmins A.C., Yau E.H., Palazzo M., Hinds C.J., Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 330:1994;1717-1722
94. Aubier M., Trippenbach T., Roussos C.H. Respiratory muscle fatigue during cardiogenic shock. J Appl Physiol. 51:1981;499-508
95. Hussain S.N.A., Simkus G., Roussos C. Respiratory muscle fatigue a cause of ventilatory failure in septic shock. J Appl Physiol. 58:1985;2033-2040
96. Viires N., Sillye G., Aubier M., Rassidakia A., Roussos C. Regional blood distribution in dog during induced hypotension and low cardiac output, spontaneous breathing vs artificial ventilation. J Clin Invest. 72:1983;935-947
97. 2 consumption in septic shock. J Appl Physiol. 62:1987;1368-1376
98. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 342:2000;1301-1308
99. Ely E.W., Baker A.M., Dungan D.P., Barker H.L., Smith A.C., Kelly P.T., et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med. 335:1996;1864-1869
100. Pérez J., Dellinger R.P. Other supportive therapies in sepsis. Intensive Care Med. 27:(suppl):2001;S116-127
101. Canadian Critical Care Trials Group, Cook D.J., Fuller H., Guyatt G.H., Marshall J.C., Leasa D., Hall R., et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med. 330:1994;377-381
102. Keane M.G., Ingenito E.P., Goldhaber S.Z. Utilization of venous thromboembolism prophylaxis in the medical intensive care unit. Chest. 106:1994;13-14
103. Bolton C.F. Sepsis and the systemic inflammatory response syndrome neuromuscular manifestations. Crit Care Med. 24:1996;1408-1416
104. De Letter M.A.A.G.J., Schmitz P.I.M., Visser L.H., Verheul F.A.M., Schellens R.L.L.A., Op de Coul D.A.W., et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med. 29:2001;2281-2286
105. Gadek J.E., DeMichele S.J., Karlstad M.D., Pacht E.R., Donahoe M., Albertson T.E., et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit Care Med. 27:1999;1409-1420
106. Marik PE, Zaloga GP. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med 2001;29:2264-70
107. Moriyama S., Okamoto K., Tabira Y., Kikuta K., Kukita I., Hamaguchi M., et al. Evaluation of oxygen consumption and resting energy expenditure in critically ill patients with systemic inflammatory response syndrome. Crit Care Med. 27:1999;2133-2136
108. ACCP Consensus Statement. Applied nutrition in ICU patients. Chest. 111:1997;769-778
109. van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 345:2001;1359-1367
110. Krinsley J.S. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc. 78:2003;1471-1478
111. Van den Berghe G., Wouters P.J., Bouillon R., Werkers F., Verwaist C., Schetz M., et al. Outcome benefit of intensive insulin therapy in the critically ill insulin dose versus glycemic control. Crit Care Med. 31:2003;359-366
112. Bone R.C. A critical evaluation of new agents for the treatment of sepsis. JAMA. 266:1991;1686-1691
113. Shapiro L., Gelfand J.A. Cytokines and sepsis pathophysiology and therapy. New Horiz. 1:1993;13-22
114. Natanson C., Esosito C.J., Banks S.M. The siren's songs of confirmatory sepsis trials selection bias and sampling error. Crit Care Med. 26:1998;1927-1931
115. Zeni F., Freeman B., Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock a reassessment. Crit Care Med. 25:1997;1095-1100
116. Metz C., Sibbald W.J. Antiinflammatory therapy for acute lung injury a review of animal and clinical studies. Chest. 100:1991;1110-1119
117. Balk R.A., Jacobs R.F., Tryka F., Walls R.C., Bone R.C. Low dose ibuprofen reverses the hemodynamic alterations of canine endotoxin shock. Crit Care Med. 16:1988;1128-1131
118. Jacobs E.R., Bone R.C., Balk R.A., Wilson J.C. Jr. Ibuprofen improves survival in sheep endotoxin shock. J.Crit Care. 3:1986;142-149
119. Bernard G.R., Wheeler A.P., Russell J.A., Schein R., Summer W.R., Steinberg K.P., et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med. 336:1997;912-918
120. Ottosson J., Brandberg A., Erikson B., Hedman L., Dawidson I., Soderberg R. Experimental septic shock effects of corticosteroids. Circ Shock. 9:1982;571-577
121. Rao P.S., Cavanagh D. Endotoxin shock in the subhuman primate some effects of methylprednisolone administration. Arch Surg. 102:1971;486-492
122. Demling R.H., Smith M., Gunther R., Wandzilak T. Endotoxin-induced lung injury in unanesthetized sheep effect of methylprednisolone. Circ Shock. 8:1981;351-360
123. Carlet J. From mega to more reasonable doses of corticosteroids a decade to recreate hope. Crit Care Med. 27:1999;672-674
124. Hinshaw L.B., Archer L.T., Beller-Todd B.K., Benjamin B., Flournoy D.J., Passey R. Survival of primates in lethal septic shock following delayed treatment with steroid. Circ Shock. 8:1981;291-300
125. Hinshaw L.B., Archer L.T., Beller-Todd B.K., Coalson J.J., Flournoy D.J., Passey R., et al. Survival of primates in LD100 septic shock following steroid/antibiotic therapy. J Surg Res. 28:1980;151-170
126. Hollenbach S.J., DeGusman L.R., Bellamy R.F. Early administration of methylprednisolone promotes survival in rats with intra-abdominal sepsis. Circ Shock. 20:1986;161-168
127. Brigham K.L., Bowers R.E., McKeen C.R. Methylprednisolone prevention of increased lung vascular permeability following endotoxemia in sheep. J Clin Invest. 67:1981;1103-1110
128. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg. 184:1976;333-339
129. Bernard G.R., Luce J.M., Sprung C.L., Rinaldo J.E., Tate R.M., Sibbald W.J., et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 317:1987;1565-1570
130. Bone R.C., Fisher C.J. Jr, Clemmer T.P., Slotman G.J., Metz C.A., Balk R.A. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 317:1987;653-658
131. Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 317:1987;659-665
132. Bone R.C., Fisher C.J. Jr, Clemmer T.P., Slotman G.J., Metz C.A. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest. 92:1987;1032-1036
133. Weigelt J.A., Norcross J.F., Borman K.R., Snyder W.H. III. Early steroid therapy for respiratory failure. Arch Surg. 120:1985;536-540
134. Sprung C.L., Caralis P.V., Marcial E.H., Pierce M., Gelbard M.A., Long W.M., et al. The effects of high-dose corticosteroids in patients with septic shock a prospective, controlled study. N Engl J Med. 311:1984;1137-1143
135. Luce J.M., Montgomery A.B., Marks J.D., Turner J., Metz C.A., Murray J.F. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 138:1988;62-68
136. Annane D., Sebille V., Troche G., Raphael J.C., Gajdos P., Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA. 283:2000;1038-1045
137. Annane D. Effects of the combination of hydrocortisone (HC)-fludrocortisone (FC) on mortality in septic shock. [abstract] Crit Care Med. 28:2000;A63
138. Yildiz O., Doganay M., Aygen B., Guven M., Keleutimur F., Tutuu A. Physiological-dose steroid therapy in sepsis. Crit Care. 6:2002;251-259
139. Annane D. Cortisol replacement for severe sepsis and septic shock what should I do? Crit Care. 6:2002;190-191
140. Abraham E., Evans T. Corticosteroids and septic shock. JAMA. 288:2002;886-887
141. Pinsky M.R., Vincent J.L., Deviere J., Alegre M., Kahn R.J., Dupont E. Serum cytokine levels in human septic shock relation to multiple-system organ failure and mortality. Chest. 103:1993;565-575
142. Abraham E., Wunderink R., Silverman H., Perl T.M., Nasraway S., Levy H., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome. JAMA. 273:1995;934-941
143. Reinhart K., Wiegand-Löhnert C., Grimminger F., Kaul M., Withington S., Treacher D., et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med. 24:1996;733-742
144. Fisher C.J. Jr, Agosti J.M., Opal S.M., Lowry S.F., Balk R.A., Sadoff J.C., et al. Treatment of septic shock with the tumor necrosis factor receptor Fc fusion protein. N Engl J Med. 334:1996;1697-1702
145. Panacek E., Marshall J.C., Fischkoff S., Barchuk W., Teoh L. Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis results of the MONARCS trial. Chest. 118:(suppl):2000;S88
146. Meyer M.M. Renal replacement therapies. Crit Care Clin. 16:2000;29-58
147. Honore P.M., Jamez J., Wauthier M., Lee P.A., Gugernier T., Pirenne B., et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med. 28:2000;3581-3587
148. Cole L., Bellomo R., Journois D., Davenport P., Baldwin I., Tipping P. High-volume haemofiltration in human septic shock. Intensive Care Med. 27:2001;978-986
149. Cole L., Bellomo R., Hart G., Journois D., Davenport P., Tipping P., et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med. 30:2002;100-106
150. Reeves J.H. A review of plasma exchange in sepsis. Blood Purif. 20:2002;282-288
151. Bjorvatn B., Bjertnaes L., Fadnes H.O., Flaegstad T., Gutteberg T.J., Kristiansen B.E., et al. Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. BMJ. 288:1984;439-441
152. Reeves J.H., Butt W.W. Blood filtration in children with severe sepsis safe adjunctive therapy. Intensive Care Med. 21:1995;500-504
153. Kumar A., Kanagasundaram N.S., Collyns T.A., Davison A.M. Plasma exchange and haemodiafiltration in fulminant meningococcal sepsis. Nephrol Dial Transplant. 13:1998;484-487
154. Natanson C., Hoffman W.D., Koev L.A., Dolan D.P., Banks S.M., Bacher J., et al. Plasma exchange does not improve survival in a canine model of human septic shock. Transfusion. 33:1993;243-248
155. Reeves J.H., Butt W.W., Shann F., Layton J.E., Stewart A., Waring P.M., et al. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med. 27:1999;2096-2104
156. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med. 28:(suppl):2000;S31-33
157. Enkhbaatar P., Okajima K., Murakami K., Uchiba M., Okabe H., Okabe K., et al. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide- induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med. 162:2000;1752-1759
158. Broze G.J. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis. 6:(suppl):1995;S7-13
159. Taylor F.B. Jr, Chang A., Esmon C.T., D'Angelo A., Vigano-D'Angelo S., Blick K.E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 79:1987;918-925
160. Taylor F.B. Jr, Peer G.T., Lockhart M.S., Ferrell G., Esmon C.T. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood. 97:2001;1685-1688
161. Taylor F.B. Jr, Stearns-Kurosawa D.J., Kurosawa S., Ferrell G., Chang A.C., Laszik Z., et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood. 95:2000;1680-1686
162. Grey S.T., Tsuchida A., Hau H., Orthner C.L., Salem H.H., Hancock W.W. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes of LPS, IFN-gamma, or phorbol ester. J Immunol. 153:1994;3664-3672
163. Fourrier F., Jourdain M., Tournoys A., Gosset P., Mangalaboyi J., Chopin C. Effects of a combined antithrombin III and protein C supplementation in porcine acute endotoxic shock. Shock. 10:1998;364-370
164. Goldfarb R.D., Glock D., Johnson K., Creasey A.A., Carr C., McCarthy R.J., et al. Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock. Shock. 10:1998;258-264
165. Fourrier F., Chopin C., Huart J.J., Runge I., Caron C., Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest. 104:1993;882-888
166. Eisele B., Lamy M., Thijs L.G., Keinecke H.O., Schuster H.P., Matthias F.R., et al. Antithrombin III in patients with severe sepsis a randomized, placebo-controlled, double-blind, multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 24:1998;663-672
167. KyberSept Trial Study Group, Warren B.L., Eid A., Singer P., Pillay S.S., Carl P., Novak I., et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis a randomized controlled trial. JAMA. 286:2001;1869-1878
168. Abraham E., Reinhart K., Svoboda P., Seibert A., Olthoff D., Dal Nogare A., et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med. 29:2001;2081-2089
169. Chiron announces results of Phase III study of tifacogin in severe sepsis [press release]. Available at: http://www.chiron.com/investor/news/index.htm. Accessed Sep 17, 2002
170. Joyce D.E., Gelbert L., Ciaccia A., DeHoff B., Grinnell B.W. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 276:2001;11199-11203
171. Bernard G.R., Ely E.W., Wright T.J., Fraiz J., Stasek J.E. Jr, Russell J.A., et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med. 29:2001;2051-2059
172. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 344:2001;699-709
173. PROWESS Investigators, Ely E.W., Laterre P.F., Angus D.C., Helterbrand J.D., Levy H., Dhainaut J.F., et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med. 31:2003;12-19
174. Manns B.J., Lee H., Doig J., Johnson D., Donaldson C. An economic
175. Beale R., Wright T.J., Wong K., Vincent J.L., Bernard. Safety of drotrecogin alfa (activated) in adult patients with severe sepsis comparison of global ENHANCE to PROWESS. Chest. 124:(suppl):2003;S102-103
176. Vincent J.L., Light B., Wright T., Wong K., Johnson G., Bernard G. Global ENHANCE results indicate organ function improvement with drotrecogin alfa (activated) in severe sepsis patients. Chest. 124:(suppl):2003;S103
177. Heyland D.K., Hopman W., Coo H., Tranmer J., McColl M.A. Long-term health related quality of life in survivors of sepsis short form 36, a valid and reliable measure of health-related quality of life. Crit Care Med. 28:2000;3599-3605